The nitrosoureas BCNU, CCNU and MeCCNU, when administered in large single doses, appear to be amongst the most effective of cytotoxic agents against a range of experimental tumours in vivo (e.g. Lewis lung carcinoma, B16 melanoma, KHT sarcoma, L1210 leukaemia), as judged by cell survival, regrowth delay and "tumour cure" endpoints (Blackett et al., 1975; Mayo et al., 1972; Schabel, 1976; Mulcahy, 1982) .
However, in a clinical context, these nitrosoureas do not appear to have fulfilled the promise that might have been expected from pre-clinical therapeutic studies. The reason for this is not clear, although it may sometimes be due to rapid development of tumour cell resistance to this class of cytotoxic agents. Development of resistance to nitrosoureas has been reported with several experimental tumours, including the Lewis lung carcinoma (Schabel, 1976) and B16 melanoma (Griswold et al., 1974) , especially when the agents are administered by the clinically relevant regime of repeated moderate doses.
In this paper we explore the response of previously untreated Lewis lung tumours to MeCCNU. The experiments allow us to construct the "complete" MeCCNU cell-survival curve down to "tumour cure" level, and to comment on the extent to which MeCCNU resistance occurs in this tumour.
Materials and methods
Mice and tumour C57B1/Cbi mice (20-25g) were obtained from the Institute of Cancer Research breeding centre. Lewis lung carcinoma (LL) was maintained in these mice by i.m. transplant of tumour brei, bilaterally into the gastrocnemius muscles (Steel & Adams, 1975) .
In excision cell survival experiments tumours were used when they weighed between 0.15 and 0.25 g, and in growth delay and "tumour cure" studies they were used at various sizes from <0.1 to 1.2g.
Cytotoxic drug and radiation treatments MeCCNU (obtained from the National Cancer Institute) was prepared as a stock solution at a concentration of 20mg ml-1 in DMSO, and stored in 0.5 ml aliquots, at -20°C. For i.p. injection into animals, MeCCNU at 1 mg ml1 was prepared by diluting an 0.5 ml aliquot of frozen stock 1 in 20 with 5% Tween 80 in PBSA. The diluted drug was always used within 15min of preparation.
In the radiation "top-up" experiments, 60Co-yirradiation was administered locally to intramuscular tumours of conscious air-breathing mice, using the animal constraining jig arrangement described in Figure 1 . To locally irradiate hypoxic tumours, mice were anaesthetized with Saffan, the blood supply to the tumour bearing leg was temporarily clamped with a loop of nylon cord and that leg was then locally irradiated using the constraining jig described by Steel et al. (1978) . For all irradiations, the dose-rate was approximately 3 Gy min-1. Dosimetry was performed using a Baldwin-Farmer substandard dosimeter.
Preparation of cell suspensions Tumour cell suspensions for in vitro cell survival assessment and in vivo lung colony assays, were prepared from aseptically excised tumour tissue by a trypsinization procedure described in detail by Figure 1 Perspex jig for local 60Co-y-irradiation of i.m. tumours. Mice were located in 4 vertically stacked, horizontal tubular chambers (7.5 cm long x 2.5 cm dia.). The tumour-bearing leg of each animal was gently pulled through a slot 1 cm wide located near the rear of the chamber, and fixed by sticking plaster to a perspex platform, so that the tumour was immediately behind a 5 cm thick perspex radiation build-up sheet. The entrance of the chamber was closed with a perspex bung. For irradiation, the jig was located on a base so that each tumour was 30cm from a tubular cobalt source (15cm long x 9.5mm dia.). The body of each mouse was shielded behind 13.5cm of lead, and scatter was minimized by a lead wedge attached to the side of the jig. . The host cells in these tumours are mainly monocytes, forming a distinct subpopulation of diameter 6 to 8.5 ,um, whereas tumour cells are greater than 9pum in diameter (see Figure 3) . When counting colonies, care was also taken to distinguish between tumour and host-derived colonies . Lung-colony assay The lung colony assay has been described in detail for the LL tumour by Steel & Adams (1977) . In this study all implants consisted of viable cells plus 106 heavily irradiated feeder cells and 106 15 gum diameter plastic microspheres. The lung cloning efficiency (CE =number of lung colonies scored per lung/number of tumour cells injected per mouse) of untreated tumour cells was in the range 3 x 10-4 to 10-3. Measurement of tumour growth delay Intramuscular tumours of untreated controls and of drug or radiation treated mice were measured sequentially 2 or 3 times per week, by passing unshaved tumour bearing legs through holes of known diameter, in a perspex disc. Leg diameters were converted to tumour wt using a calibration curve relating measured leg diameter to dissected tumour wt. Since some tumours did not shrink significantly after treatment, tumour volume responses were determined by measuring the time to regrow to 4 x their pretreatment volume (T4X), and then calculating growth delays as (median T4X of treated tumours) -(median T4X of untreated controls). For tumours that were not palpable ( < 0.1 g) at the time of treatment, growth delay was determined at a target size of 0.5 g.
Criterion for "tumour cure" "Tumour cure" was deemed to have been achieved if a leg which had been shown by measurement to contain a tumour, shrank to the size of a normal leg (6mm) and remained without sign of any tumour regrowth for more than 50 days. This time is approximately that required for a single untreated cell, implanted i.m. with 106 irradiated feeder cells, to yield a 1 g tumour. As a safeguard against false-positive cure results in the experiment where tumours were treated before they became palpable, the untreated controls and low-dose, noncurative treatment groups, were all carefully observed and each found to have 100% takes. 
Prediction of tumour cure by MeCCNU
In order to predict "tumour cure rates" by MeCCNU, it is necessary to know the inherent sensitivity of tumour cells to the drug (Figure 2 ) and the maximum number of cells which need to be killed for a tumour to be cured (i.e. the number of stem cells per tumour). Tumour stem cellularity was estimated using the cell size data shown in Figure 3 . This is a typical size profile for a trypsinized LL tumour suspension. Figure 4 and growth delay in Figure 5 . The data in Figure 4 show that higher drug doses are required for cure than predicted aboveI cellularit achieved MeCCNU dose (mg kg1) Figure 5 Growth delay curves for LL tumours treated with MeCCNU at various sizes (symbols as in Figure 4 ).
sizes "cures" were very infrequent. The regrowth delay data in Figure 5 suggest that this might be due to the presence within these tumours of a resistant subpopulation of tumour cells. Figure 2 ). Limitations on the number of cells that own in Figure 2 to Figure 6 , show as but this is substantially reduced when they are (1978) and Shipley et al. (1983) . To obtain the log cell kill due to MeCCNU, the cell kill attributable to radiation was subtracted from the total log cell _,_____________________ 0kill required to cure an 0.2 g tumour (Table I) . 15-40mgkg-1 yields a D1o value of 26mgkg-1 aComputer fit by method of Suit et al. (1964) .
bRadiation equivalent log kill= -log10 (radiation equivalent SF).
cMeCCNU equivalent log kill= total log kill required to cure 50% of tumours -Radiation equivalent log kill.
Total log kill required to cure 50% of tumours = -logl0 (95% CL 12-40) and the incidence of resistant cells is 1-in 105.
Discussion
We have used a variety of approaches in order to define the "complete" MeCCNU survival curve in previously untreated i.m. LL tumours. At low drug doses (<8 mg kg-1) cell sensitivity was measured directly using an excision cell survival assay and a modification of the lung colony assay. The majority of the tumour cells appeared by these assays to be highly drug sensitive (D10 % 2mg kg- MeCCNU doses comes from the strongly biphasic nature of the growth delay response in LL tumours and the radiation "top-up" experiment. In this experiment, the effect of high MeCCNU doses was estimated indirectly by measuring the additional radiation-induced cell killing required to "cure" the tumours. Assumptions had to be made concerning the clonogenic cell content of the tumours before treatment and the radiosensitivity of MeCCNU survivors to the "top-up" gamma-ray dose. The validity of these assumptions was tested by performing the "top-up" experiment with a low MeCCNU dose (7.5mgkg-1) which had been used in direct excision cell survival assays. The agreement between direct assay and "top-up" data was reasonable, so that at higher MeCCNU doses it was possible to predict a survival curve with a D1o at least 10 times greater than that measured at low doses (i.e. -25 mg kg 1). However, the number of MeCCNU resistant cells constituted only -0.001% of all cells in previously untreated tumours.
From the studies presented here it is not possible to comment on the nature, or origin, of the resistance leading to the biphasic MeCCNU survival curve, although this has been examined, and will be described later. Apart from the work of Schabel (1976) and Griswold et al. (1974) , utilizing multiple treatment regimes, we are aware of only one other bifunctional nitrosourea survival curve which appears to demonstrate drug resistance in previously untreated tumours. Mulcahy et al. (1982) reported a biphasic excision cell survival curve for KHT tumours treated with BCNU. Although the slope of the resistant tail cannot be evaluated, it would appear that < 1 in 104 cells exhibited resistance to BCNU. Whether the poor clinical performance of the nitrosoureas is due to a tendency for rapid development of drug resistance is not clear.
